Second-line treatment for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs for people with advanced liver cancer that has progressed after first-line treatment. It aims to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of liver cancer (hepatocellular carcinoma).
- You must be between 18 and 75 years old.
- You must have had at least one standard first-line treatment (like immunotherapy combined with anti-angiogenesis therapy) that didn't work or caused unacceptable side effects.
- You must have at least one tumor that can be measured on scans.
- Your liver function must be adequate (Child-Pugh class A or B7).
- You must be physically able to care for yourself (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called AK112 for people with advanced liver cancer that hasn't spread to the brain or key blood vessels. It may be an option if you haven't had immunotherapy before and your liver is still working well.
This trial is testing a new combination of drugs (an immunotherapy called AK104 plus a targeted therapy called lenvatinib) compared to lenvatinib alone, for people whose liver cancer has grown after they received the standard first-line treatment with atezolizumab and bevacizumab. The goal is to see if combining the two drugs can better control the cancer and help patients live longer.
This trial tests if adding a new combination of drugs (AK104 and lenvatinib) to a standard liver cancer procedure called TACE is more effective than TACE alone. It is for people whose liver cancer has not spread and cannot be removed by surgery, but who are well enough to receive these treatments.
This trial tests whether AK104, taken after liver cancer surgery, can lower the chance that the cancer returns. It is for people with high risk of recurrence but no remaining cancer after surgery.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.